Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

SIMPLE SUMMARY: Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have been established to date. Previous comprehensive...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Wiele, Andrew J., Surasi, Devaki Shilpa, Rao, Priya, Sircar, Kanishka, Su, Xiaoping, Bathala, Tharakeswara K., Shah, Amishi Y., Jonasch, Eric, Cataldo, Vince D., Genovese, Giannicola, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Msaouel, Pavlos
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://ncbi.nlm.nih.gov/pubmed/33946504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13092170
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires